Roff C F, Goldin E, Comly M E, Cooney A, Brown A, Vanier M T, Miller S P, Brady R O, Pentchev P G
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.
Dev Neurosci. 1991;13(4-5):315-9. doi: 10.1159/000112179.
Niemann-Pick Type C (NPC) disease is a cholesterol lipidosis resulting from defective postlysosomal cholesterol transport. In normal cells this segment of cholesterol trafficking is inhibited by treatment with either U18666A or imipramine. Other compounds are also capable of blocking postlysosomal cholesterol transport: stearylamine, RV-538, and sphinganine inhibit low-density lipoprotein-induced esterification of cholesterol and cause unesterified cholesterol to accumulate in perinuclear vesicles. These vesicles can be stained with filipin to give a staining pattern indistinguishable from that seen in NPC fibroblasts. Because all of these compounds are hydrophobic amines, we conclude that most, if not all, hydrophobic amines block the postlysosomal transport of cholesterol. These results also raise the possibility that an endogenous amine, e.g., sphinganine, may inhibit cholesterol transport in NPC.
尼曼-匹克C型(NPC)病是一种由于溶酶体后胆固醇转运缺陷导致的胆固醇脂质沉积症。在正常细胞中,这一胆固醇转运片段可被U18666A或丙咪嗪处理所抑制。其他化合物也能够阻断溶酶体后胆固醇转运:硬脂胺、RV-538和鞘氨醇抑制低密度脂蛋白诱导的胆固醇酯化,并导致未酯化胆固醇在核周小泡中积聚。这些小泡可用制霉菌素染色,染色模式与NPC成纤维细胞中所见的无法区分。由于所有这些化合物都是疏水胺,我们得出结论,大多数(如果不是全部)疏水胺会阻断溶酶体后胆固醇转运。这些结果还增加了一种可能性,即内源性胺类,如鞘氨醇,可能会抑制NPC中的胆固醇转运。